Treatment of insulin resistance: straight from the gut

Drug Discovery Today

Volumn 21, Issue 8, 2016, Pages 1284-1290

  Zhang, Xueli ^a   Zheng, Xiao ^b   Yuan, Yang ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

GASTROINTESTINAL SURGERY; GASTROINTESTINAL TRACT; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; METABOLIC DISORDER; MOLECULE; REVIEW; ANIMAL; METABOLISM;

ANIMALS; GASTROINTESTINAL TRACT; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE;

EID: 84979665351     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.06.016     Document Type: Review

References (71)

1. Sell, H., et al. The adipocyte-myocyte axis in insulin resistance. Trends Endocrinol. Metab. 17 (2006), 416–422.
2. Perry, R.J., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
3. Schwartz, M.W., et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 503 (2013), 59–66.
4. Dumas, M.E., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12511–12516.
5. Johnson, A.M., Olefsky, J.M., The origins and drivers of insulin resistance. Cell 152 (2013), 673–684.
6. De Vadder, F., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156 (2014), 84–96.
7. Silvestri, C., Di Marzo, V., The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 17 (2013), 475–490.
8. Young, R.L., et al. Gut serotonin is a regulator of obesity and metabolism. Gastroenterology 149 (2015), 253–255.
9. Kuipers, F., et al. Beyond intestinal soap-bile acids in metabolic control. Nat. Rev. Endocrinol. 10 (2014), 488–498.
10. Duca, F.A., et al. Glucoregulatory relevance of small intestinal nutrient sensing in physiology, bariatric surgery, and pharmacology. Cell Metab. 22 (2015), 367–380.
11. Rasmussen, B.A., et al. Jejunal leptin-PI3K signaling lowers glucose production. Cell Metab. 19 (2014), 155–161.
12. Ryan, K.K., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
13. Duca, F.A., et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 21 (2015), 506–511.
14. Cote, C.D., et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21 (2015), 498–505.
15. Breen, D.M., et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat. Med. 18 (2012), 950–955.
16. Li, F., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun., 4, 2013, 2384.
17. Jiang, C., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun., 6, 2015, 10166.
18. Luck, H., et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 21 (2015), 527–542.
19. Haghikia, A., et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43 (2015), 817–829.
20. Henao-Mejia, J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
21. Brestoff, J.R., Artis, D., Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14 (2013), 676–684.
22. Vrieze, A., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916 e917.
23. Cani, P.D., Delzenne, N.M., The gut microbiome as therapeutic target. Pharmacol. Ther. 130 (2011), 202–212.
24. Karlsson, F.H., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498 (2013), 99–103.
25. Qin, J., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490 (2012), 55–60.
26. Suez, J., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514 (2014), 181–186.
27. Chassaing, B., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519 (2015), 92–96.
28. Xu, J., et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 9 (2015), 552–562.
29. Shin, N.R., et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63 (2014), 727–735.
30. Chang, C.J., et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat. Commun., 6, 2015, 7489.
31. Khan, M.T., et al. Microbial modulation of insulin sensitivity. Cell Metab. 20 (2014), 753–760.
32. Canfora, E.E., et al. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 (2015), 577–591.
33. Sharon, G., et al. Specialized metabolites from the microbiome in health and disease. Cell Metab. 20 (2014), 719–730.
34. Fiorucci, S., Distrutti, E., Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol. Med. 21 (2015), 702–714.
35. Psichas, A., et al. Gut chemosensing mechanisms. J. Clin. Invest. 125 (2015), 908–917.
36. Fang, S., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21 (2015), 159–165.
37. Everard, A., et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat. Commun., 5, 2014, 5648.
38. Hooper, L.V., et al. Interactions between the microbiota and the immune system. Science 336 (2012), 1268–1273.
39. Yano, J.M., et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 (2015), 264–276.
40. Sumara, G., et al. Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metab. 16 (2012), 588–600.
41. Crane, J.D., et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat. Med. 21 (2015), 166–172.
42. Fournel, A., et al. Apelin targets gut contraction to control glucose metabolism via the brain. Gut, 2015, 10.1136/gutjnl-2015-310230.
43. Flynn, C.R., et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat. Commun., 6, 2015, 7715.
44. Osto, E., et al. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation 131 (2015), 871–881.
45. Liou, A.P., et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med., 5, 2013, 178ra141.
46. Tremaroli, V., et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22 (2015), 228–238.
47. Magalhaes, I., et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J. Clin. Invest. 125 (2015), 1752–1762.
48. Wang, J., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 9 (2015), 1–15.
49. Roopchand, D.E., et al. Dietary polyphenols promote growth of the gut bacterium Akkermansia muciniphila and attenuate high-fat diet-induced metabolic syndrome. Diabetes 64 (2015), 2847–2858.
50. Geurts, L., et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef. Microbes 5 (2014), 3–17.
51. Aitken, J.D., Gewirtz, A.T., Gut microbiota in 2012: toward understanding and manipulating the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 72–74.
52. Brahe, L.K., et al. Dietary modulation of the gut microbiota-a randomised controlled trial in obese postmenopausal women. Br. J. Nutr. 114 (2015), 406–417.
53. Sayin, S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17 (2013), 225–235.
54. Osorio, J., Diabetes: a closer look at the mechanisms of action of colesevelam in humans. Nat. Rev. Endocrinol., 8, 2012, 128.
55. Cani, P.D., et al. Endocannabinoids – at the crossroads between the gut microbiota and host metabolism. Nat. Rev. Endocrinol. 12 (2016), 133–143.
56. Everard, A., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9066–9071.
57. Wang, X., et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514 (2014), 237–241.
58. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
59. Rysz, J., et al. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin. Investig. Drugs 24 (2015), 603–610.
60. Mudaliar, S., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582 e571.
61. Gillum, M.P., et al. N-acylphosphatidylethanolamine, a gut-derived circulating factor induced by fat ingestion, inhibits food intake. Cell 135 (2008), 813–824.
62. Chen, Z., et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Invest. 124 (2014), 3391–3406.
63. Hao, H., et al. Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol. Sci. 35 (2014), 168–177.
64. Chen, F., et al. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?. J. Ethnopharmacol. 179 (2016), 253–264.
65. Cully, M., Obesity and diabetes: FXR and JAK step up to BAT. Nat. Rev. Drug Discov., 14, 2015, 91.
66. Scheen, A.J., Van Gaal, L.F., Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2 (2014), 911–922.
67. Levy, M., et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163 (2015), 1428–1443.
68. Murphy, E.F., et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 62 (2013), 220–226.
69. Wu, H., et al. Linking microbiota to human diseases: a systems biology perspective. Trends Endocrinol. Metab. 26 (2015), 758–770.
70. Garber, K., Drugging the gut microbiome. Nat. Biotechnol. 33 (2015), 228–231.
71. Ghishan, F.K., Kiela, P.R., From probiotics to therapeutics: another step forward?. J. Clin. Invest. 121 (2011), 2149–2152.